MediGene appoints new Executive Board Member for Research & Development

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Martinsried/Munich May 21, 2008. MediGene AG (Frankfurt, Prime
Standard: MDG) announces that Dr. Axel Mescheder has been appointed
the new Executive Board Member for Research & Development. Dr.
Mescheder, previously head of Clinical Research & Development at
MediGene, will take over the position of Executive Board Member from
Dr. Ulrich Delvos, who will be resigning from the firm by mutual
amicable agreement with the Company. Dr. Mescheder is a medical
specialist in pharmacology and toxicology and has more than 15 years
of management experience in clinical research & development at
international pharmaceutical and biotech companies.

Dr. Peter Heinrich, Chairman of the Executive Board of MediGene AG,
comments: "We are very pleased that Dr. Axel Mescheder will be
assuming the important role of Executive Board Member for Research &
Development. As head of clinical development for many years, he was
responsible among other things for the successful development of our
Veregen(TM) medication, which is available on the US market as the
first proprietary development from a German biotech company. He also
headed up the clinical development program of EndoTAG(TM)-1, which
features impressive phase II data in the treatment of pancreatic
cancer. I would like to express my sincere thanks to Dr. Ulrich
Delvos for the valuable contributions he made during his four years
on the Executive Board of MediGene and for the significant progress
he achieved in MediGene's research & development department."

Axel Mescheder M. D. studied human medicine in Kiel and Cincinnati,
USA, and received his license to practice medicine in 1986. Following
his many years of medical and scientific work at the University
Clinic of Kiel, the physician and medical specialist complete with
doctor's degree started his industrial career as Medical and Product
Manager at Hoffmann - La Roche AG, Grenzach/Germany in 1993. In 1997
he joined Aventis Behring, (Marburg, King of Prussia, USA), as the
head of Intensive Care Europe before taking over the role of Director
Clinical Research & Development at Genetic Institute GmbH, (Munich,
Boston, USA), which was acquired by Wyeth International Pharma, in
1999. From 2001 to 2003, Dr. Mescheder served as Medical Director of
MorphoSys AG, Martinsried/Germany. In February 2003 he joined
MediGene AG as Vice President Clinical Research & Development.

Dr. Axel Mescheder, the new Executive Director of Research &
Development at MediGene, comments: "I see a great deal of potential
in MediGene's research and development projects and hold this company
and its competent employees in extremely high esteem. I am therefore
grateful that this challenging task has now been assigned to me and I
very much look forward to further advancing the research &
development of MediGene AG."

This press release contains forward-looking statements. The
forward-looking statements contained herein represent the judgment of
MediGene as of the date of this release. The actual results achieved
by MediGene may significantly differ from the statements made in
these forward-looking statements. MediGene disclaims any obligation
to update any of these forward-looking statements. MediGene(TM),
EndoTAG(TM), and Veregen(TM) are trademarks of MediGene AG,
Polyphenon® is a registered trademark of Mitsui Norin Co., Ltd.,
Oracea® is a registered trademark of CollaGenex Pharmaceuticals Inc.,
Eligard® is a registered trademark of QLT USA, Inc. These trademarks
may be owned or licensed in select locations only.

- ends -

MediGene AG is a publicly quoted (Frankfurt, Prime Standard: MDG)
biotechnology company located in Martinsried/Munich, Germany, with
subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first
German biotech company to have drugs on the market, which are being
distributed by partner companies. Another drug candidate has just
received official recommendation for marketing authorization by the
EMEA. MediGene is planning to start its own marketing activities. The
company has several drug candidates in clinical development,
including two products which each have an annual sales potential of
more than one billion Euros per year. MediGene also has projects in
research and pre-clinical development and possesses innovative
platform technologies for the development of active ingredients.
MediGene concentrates on researching, developing and commercializing
novel drugs in three therapeutic areas: cancer, autoimmune diseases,
and skin diseases.

Contact MediGene AG
E-mail: investor@medigene.com
Fax:++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Georg Dönges, Public Relations, Tel.: ++49 - 89 -
85 65 - 3317
Dr. Michael Nettersheim / Dr. Georg Dönges, Investor Relations, Tel.:
++49 - 89 - 85 65 - 2946

--- End of Message ---

MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN:
502090; ISIN: DE0005020903 ; Index: Prime All Share, CDAX, TECH All
Share, HDAX, MIDCAP, TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in
Bayerische Börse München,
Freiverkehr in Börse Düsseldorf, Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr
in Niedersächsische Börse zu Hannover,
Geregelter Markt in Frankfurter Wertpapierbörse;
Copyright © Hugin AS 2008. All rights reserved.